-67.4%
IREN vs MRNA
+945.0%
-1,012.4%
-71.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -11.2% | +13.1% | -24.3% | -12.1% |
| 7D | -24.7% | +20.6% | -45.4% | -25.7% |
| 30D | -46.4% | +27.1% | -73.5% | -47.3% |
| 3M | -46.9% | +353.4% | -400.2% | -55.8% |
| 6M | -56.1% | +446.3% | -502.4% | -67.8% |
| YTD | -42.5% | +776.2% | -818.7% | -64.5% |
| 1Y | -67.4% | +987.9% | -1,055.3% | -81.0% |
| All | -67.4% | +945.0% | -1,012.4% | -81.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling